Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1996-11-12
pubmed:abstractText
The aim of the present study was to determine whether diabetes-induced changes in the distribution of enteric neuropeptides, could be prevented in 12-week streptozotocin-diabetic rats, by rigorous control of glycaemia, using daily adminstration of insulin, or an aldose reductase inhibitor (ponalrestat). The pattern of distribution of nerve fibres and cell bodies, containing immunoreactive vasoactive intestinal polypeptide (VIP), galanin (GAL), calcitonin gene-related peptide (CGRP) and substance P was examined in the myenteric plexus of ileum from control, untreated diabetic, insulin-treated diabetic and aldose reductase inhibitor-treated diabetic rats. The increase in VIP- and GAL-like immunoreactivity, seen in the myenteric plexus of untreated diabetic rat ileum, was not present in the myenteric plexus of ileum from insulin- and aldose reductase inhibitor-treated diabetic rats. With CGRP-like immunoreactive fibres, there was a clear decrease in the ileum of untreated diabetic rats. This was prevented by insulin treatment, but aldose reductase inhibitor treatment had no effect. No alterations in substance P-like immunoreactivity were seen in the myenteric plexus of ileum from any of the groups investigated. Generally, the similarity of effect of ponalrestat and insulin on VIP and galanin expression in this study supports a primary effect of insulin via glycaemic control. The dissimilarity of the effect of the two treatments on CGRP expression may imply a neurotrophic effect of insulin, although there are certainly consequences of hyperglycaemia other than exaggerated flux through the polyol pathway.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0165-1838
pubmed:author
pubmed:issnType
Print
pubmed:day
6
pubmed:volume
58
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
163-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:8738309-Aldehyde Reductase, pubmed-meshheading:8738309-Animals, pubmed-meshheading:8738309-Antibody Specificity, pubmed-meshheading:8738309-Axons, pubmed-meshheading:8738309-Calcitonin Gene-Related Peptide, pubmed-meshheading:8738309-Diabetes Mellitus, Experimental, pubmed-meshheading:8738309-Galanin, pubmed-meshheading:8738309-Hypoglycemic Agents, pubmed-meshheading:8738309-Ileum, pubmed-meshheading:8738309-Immunohistochemistry, pubmed-meshheading:8738309-Insulin, pubmed-meshheading:8738309-Intestines, pubmed-meshheading:8738309-Male, pubmed-meshheading:8738309-Myenteric Plexus, pubmed-meshheading:8738309-Neurons, pubmed-meshheading:8738309-Neuropeptides, pubmed-meshheading:8738309-Phthalazines, pubmed-meshheading:8738309-Rats, pubmed-meshheading:8738309-Rats, Wistar, pubmed-meshheading:8738309-Substance P, pubmed-meshheading:8738309-Vasoactive Intestinal Peptide
pubmed:year
1996
pubmed:articleTitle
Enteric neuropeptides in streptozotocin-diabetic rats; effects of insulin and aldose reductase inhibition.
pubmed:affiliation
Department of Anatomy and Developmental Biology, University College London, UK.
pubmed:publicationType
Journal Article